The life science ecosystem thrives on access to patient samples and data for breakthrough, patient-centric research. Yet, many researchers face significant barriers, including institutional restrictions and inconsistent protocols. The MLSC is in the early stages of evaluating a Biobank initiative that seeks to break barriers by establishing disease-specific, accessible biobanks sourced from diverse patient populations across Massachusetts.

By addressing longstanding challenges in accessing samples and data, this effort has the potential to empower startups, mid-sized companies, pharmaceutical firms, and translational researchers to accelerate innovation in diagnostics and therapeutics.

Currently, we are gathering insights from startups and translational researchers to determine the first-year disease focus. In collaboration with institutions across the state, the MLSC is working to support the development of a broadly accessible biobank that could benefit both non-profit and for-profit organizations seeking high-quality patient samples and data.